Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea flag South Korea · Delayed Price · Currency is KRW
14,630
-130 (-0.88%)
At close: Nov 6, 2026

Cell Biotech Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
60,39953,12649,91353,78750,52646,873
Revenue Growth
27.27%6.44%-7.20%6.46%7.79%2.83%
Gross Profit
43,68138,35635,81138,64937,67235,475
Operating Income
10,0977,9146,7962,1956,0517,257
Net Income
16,80010,12515,1276,3048,28110,383
Earnings Per Share
2454.001479.002210.00921.001201.001468.00
EPS Growth
65.98%-33.08%139.96%-23.31%-18.19%226.54%

Revenue by Segment

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Finished Product Business
94,81582,49073,39348,60344,72940,352
Raw Material Business Division
4,7125,4975,5295,1845,7976,521
Internal Sales
--34,861-29,009---
Total
60,39953,12649,91353,78750,52646,873

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
96,38493,06287,45470,33265,36857,834
Total Debt
158.86425.381,0171,555958.57826.38
Net Cash (Debt)
96,22592,63686,43768,77764,40957,007
Net Cash Growth
12.72%7.17%25.68%6.78%12.98%6.47%
Net Cash Per Share
14059.9513535.6012629.7410049.379342.068061.43

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
18,08311,10919,2677,81512,81414,892
Capital Expenditures
-7,255-3,105-1,129-1,552-2,368-848.59
Free Cash Flow
10,8288,00418,1386,26410,44514,044
Free Cash Flow Growth
11.22%-55.87%189.57%-40.03%-25.62%116.55%

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
72.32%72.20%71.75%71.85%74.56%75.68%
Operating Margin
16.72%14.90%13.62%4.08%11.98%15.48%
Pretax Margin
32.50%21.18%31.27%12.79%20.13%25.79%
Profit Margin
27.82%19.06%30.31%11.72%16.39%22.15%
FCF Margin
17.93%15.07%36.34%11.65%20.67%29.96%

Dividends

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Dividend Per Share
600.000600.000450.000450.000450.000450.000
Dividend Per Share Growth
33.33%33.33%0%0%0%0%
Dividend Yield
4.10%4.58%3.15%4.01%3.54%2.39%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
5.968.866.4612.1810.5012.84
Forward PE
-8.168.168.168.168.16
P/FCF Ratio
9.3311.215.3812.268.329.49
PS Ratio
1.671.691.961.431.722.84